What Is Retatide (Retatrutide)?
Retatide (retatrutide) is a triple-agonist peptide that activates GLP-1, GIP, and glucagon receptors simultaneously — showing up to 24% body weight loss and 80% reduction in liver fat in clinical trials.
Retatide — also called retatrutide — is a triple-agonist peptide. Semaglutide hits one receptor. Tirzepatide hits two. Retatide hits three. And the clinical trial results have been unlike anything seen before in the weight loss and metabolic space.
It's not yet FDA-approved, but it's in late-stage clinical trials and the data has gotten the attention of essentially everyone in metabolic medicine.
The Three Receptors
Retatide activates:
1. GLP-1 (Glucagon-Like Peptide 1)
The same receptor semaglutide and tirzepatide hit. Appetite suppression, insulin management, slowed gastric emptying. This is the proven foundation.
2. GIP (Glucose-Dependent Insulinotropic Polypeptide)
The same second receptor tirzepatide adds. Enhances insulin sensitivity and fat metabolism beyond what GLP-1 alone achieves.
3. Glucagon Receptor
This is the new addition. Glucagon is a hormone that does the opposite of insulin — it tells your body to break down stored energy (glycogen and fat) and use it for fuel. Activating the glucagon receptor:
- Increases metabolic rate — your body burns more calories at rest
- Promotes fat mobilization — stored fat gets broken down and used for energy
- Supports liver fat reduction — glucagon directly signals the liver to reduce fat storage
This third receptor is what sets retatide apart. Semaglutide and tirzepatide primarily reduce caloric intake (you eat less). Retatide does that AND increases caloric expenditure (you burn more). It works both sides of the energy equation.
Why the Results Are Unprecedented
Phase 2 Trial Data (Human)
The Phase 2 clinical trial results for retatide were published and they turned heads:
- Participants at the highest dose lost an average of 24.2% of their body weight over 48 weeks
- Some participants lost over 30% of their body weight
- Liver fat reduced by up to 80% — that's not a typo
- Visceral fat (the dangerous fat around your organs) showed significant direct reduction
- Metabolic rate was maintained or increased even while in caloric deficit
That last point is critical. With most diets and even with semaglutide, your metabolic rate drops as you lose weight — your body tries to conserve energy. Retatide's glucagon receptor activation appears to counteract this, keeping your metabolism from tanking during weight loss.
Comparison to Existing Drugs
- Semaglutide: ~15-17% weight loss
- Tirzepatide: ~22% weight loss
- Retatide: ~24% weight loss (with some individuals exceeding 30%)
But weight loss percentages don't capture the full story. The liver fat reduction, maintained metabolic rate, and direct visceral fat targeting make retatide qualitatively different, not just quantitatively better.
How Retatide Works Day to Day
Like semaglutide and tirzepatide, retatide is a once-weekly subcutaneous injection with gradual dose escalation. In clinical trials:
- Starting dose: 0.5 mg/week
- Gradual increases over weeks
- Maximum tested dose: 12 mg/week
- The dose ramp minimizes GI side effects (same approach as the other GLP-1 drugs)
Side Effects (From Clinical Trials)
Common:
- Nausea — the most frequent, particularly during dose escalation
- Diarrhea
- Vomiting
- Decreased appetite
- Constipation
The GI side effect profile is similar to semaglutide and tirzepatide. The glucagon receptor activation doesn't appear to add significantly different side effects in the trial data so far.
Concerns being watched:
- Heart rate increases — glucagon receptor activation can increase heart rate; this is being monitored in ongoing trials
- The same thyroid concern (boxed warning territory) that applies to all GLP-1 agonists based on rodent data
- Muscle mass preservation during significant weight loss (same issue as all drugs in this class)
- Long-term safety data doesn't exist yet — the drug is still in trials
Where Retatide Stands Right Now
Regulatory status: Not FDA-approved. Currently in Phase 3 clinical trials (the final stage before potential approval). Eli Lilly is developing it.
Expected approvals: Likely being pursued for obesity, type 2 diabetes, and possibly non-alcoholic steatohepatitis (NASH/fatty liver disease) and knee osteoarthritis.
Availability: Not officially available through pharmacies or prescriptions yet. However, people have obtained research-grade retatide through peptide suppliers. Some compounding pharmacies may also be producing it. This is the research chemical gray area — the same regulatory space where many peptides exist before (and sometimes after) FDA approval.
What This Means for the GLP-1 Space
The progression is clear:
- Single agonist (semaglutide) → good results
- Dual agonist (tirzepatide) → better results
- Triple agonist (retatide) → best results so far
Each additional receptor activation adds a new dimension to the metabolic effect. Retatide doesn't just suppress appetite more effectively — it fundamentally changes the metabolic equation by increasing energy expenditure and directly mobilizing fat stores.
This drug, if approved, could change the standard of care for obesity, fatty liver disease, and metabolic syndrome.
The Bottom Line
Retatide is a triple-agonist peptide that hits GLP-1, GIP, and glucagon receptors. The addition of the glucagon receptor means it doesn't just make you eat less — it makes you burn more and directly mobilizes fat, including liver and visceral fat. Phase 2 trial results showed up to 24% average weight loss, 80% liver fat reduction, and maintained metabolic rate during caloric deficit.
It's not approved yet. Long-term safety data doesn't exist. But the clinical data so far is the most impressive in the history of metabolic pharmacology. If you're watching the peptide space, retatide is the one to follow.